Newer therapies for the treatment of asthma.

As the pathophysiology of asthma becomes better understood, a specific course of therapy can be directed to the underlying cause of asthma and not just to the signs and symptoms of asthma. This article presents medications available for physicians to use in their armamentarium to prevent the asthmatic patient from experiencing the inconvenience and frustration of repeated asthma attacks.

Using statistical process control charts for the continual improvement of asthma care.

BACKGROUND: Home monitoring of lung function using simple, inexpensive tools to measure peak expiratory flow rate (PEFR) has been possible since the 1970s. Yet although current national and international guidelines recommend monitoring of PEFRs via traditional run charts, their use by both patients and physicians remains low. The role of statistical process control (SPC) theory and charts in the serial monitoring of lung function at home were explored and applied to the direct care of patients with asthma. The method represents an integration of collective professional and improvement knowledge with the related disciplines of continual improvement, SPC, system thinking/system dynamics, paradigms, and the learning community/organization. CASE STUDIES: Use of PEFR control charts for four patients cared for at the Asthma-Allergy Clinic and Research Center (Shreveport, La) is described. The key to good asthma control is the ability to optimize lung function by reducing the variation between serial lung function measurements and thereby generate a safe range of function. Knowledge of the type of variation (special cause or common cause) in the system helps in focusing clinical decision making. Case 4, an 11-year-old boy, for example, shows how control charts were used to learn the effects of a new inhaled corticosteroid. Comparison of the last 14 days of baseline and the last 14 days of open label use of the inhaled corticosteroid showed an obvious improvement in actual PEFR values--which a run chart or comparison of means would have easily demonstrated. The control chart showed that this child's care process at baseline was functionally at risk for severe asthma (46% personal best) and that the effect of the new medication not only elevated the mean function but shifted the range of function from 46%-72% personal best to 78%-102% personal best. At this new range of function the patient's system of care was not capable of delivering values that are at risk for severe asthma. Unless the range of function the change in care is capable of producing is specifically quantitated, misinterpretation of improvement data can occur. DISCUSSION: Developing the concept of the PEFR control chart involved examining and challenging traditional mental models for monitoring PEFR at home in the care of asthma, acquiring a better understanding of the workings of dynamic systems and with system thinking, and sharing what was learned with patients and seeking their input. CONCLUSIONS: The PEFR control chart employs an interesting statistical platform that enables the integration of knowledge of serial measurements and knowledge of the variation between those measurements into a tool with which to better assess the asthma care process being followed. This tool provides clinical insights, practical knowledge, and opportunities unavailable to patients and physicians via traditional PEFR charting.

Peak expiratory flow rate control chart in asthma care: chart construction and use in asthma care.

BACKGROUND: The home monitoring of peak expiratory flow rate (PEFR), although recommended in current asthma guidelines, remains seriously underutilized by both patients and physicians. Our assessment is that this is more a statement regarding the inability of current charting methods to fulfill the promises made for PEFR monitoring, rather than a commentary regarding the usefulness of peak expiratory flow rate monitoring per se. We have adapted the theory and charting tool of the discipline of statistical process control to the daily monitoring of PEFR in the care of patients with asthma. Statistical process control charts integrate the actual PEFR values and their day-to-day variation in a manner that permits more informed decision-making. This article introduces our adaptation of statistical process control theory and charts via three case presentations. OBJECTIVE: Report our experience in the use of statistical process control theory and charting to the monitoring of peak expiratory flow in the care of patients with asthma. METHODS: Discussion of methodology and case reports. CONCLUSION: This is the first report of the application of statistical process control (SPC) theory and charting to the home monitoring of peak expiratory flow rate and the clinical decision-making processes involved in the day-to-day care of patients with asthma. SPC charts integrate knowledge of actual serial PEFR measurements with knowledge of their associated serial variation. Our adaptation of this theory and its charting methodology results in a tool that loses nothing provided by the charting methods suggested in current guidelines and, at the same time, provides patient specific, statistically driven signals of significant change; facilitates identification of the reason(s) for the change in PEFR; predicts the range in which future function will occur; permits decision-making and care to be provided in an anticipatory manner; and, importantly, permits the early identification of the functionally at-risk patient. This report demonstrates that home monitoring of peak expiratory flow is a robust tool whose usefulness in the care of patients with asthma has been limited more by the paradigm in which we have required it be used than by any of the limitations of the measurement per se.

Double-blind, placebo-controlled study of terfenadine and hydroxyzine in patients with chronic idiopathic urticaria.

Results of a double-blind, randomized, placebo-controlled, parallel study in 37 patients indicate that terfenadine, 60 mg bid, is significantly more effective than placebo and as effective as hydroxyzine, 25 mg qid, in the treatment of chronic idiopathic urticaria without causing the somnolence that was associated with the use of hydroxyzine.